Neurogene NGNE
NASDAQ NGNE
$26.55 -1.27 (-4.57%)
At close: Oct 1, 2026 · 4:00 PM EDT

Neurogene (NGNE) Preferred Stock Liabilities (2013 - 2022)

Updated

Neurogene's Preferred Stock Liabilities came in at $244.37 million for Q4 2022, up 37.4% from $177.91 million a year earlier.

Analysis

Neurogene (NGNE) Preferred Stock Liabilities (2013 - 2022) Analysis & Trends

  • Going back by year, Preferred Stock Liabilities was $177.91 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Neurogene 627.40 Mn 627.40 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 244.37 Mn
Dec 31, 2021 177.91 Mn
Dec 31, 2013 73.86 Mn
API Access

Neurogene Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=NGNE&period=max&api_key=YOUR_API_KEY